{"id":"W2755049090","doi":"10.1136/annrheumdis-2017-eular.2443","title":"OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"AbbVie; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tofacitinib; Psoriatic arthritis; Janus kinase inhibitor; Discontinuation; Internal medicine; Psoriasis Area and Severity Index; Psoriasis; Adverse effect; Placebo; Clinical endpoint; Rheumatoid arthritis; Gastroenterology; Surgery; Randomized controlled trial; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641642,0.001525991,0.002808658,0.0004008848,0.0004238702,0.001506599,0.0008579837,0.001895926,0.006000037],"category_scores_gemma":[0.00165284,0.0006426194,0.00214427,0.0004557384,0.001165014,0.001488656,0.0003087561,0.002848207,0.001152481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005806665,"about_ca_system_score_gemma":0.0009489667,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007034453,"about_ca_topic_score_gemma":0.00149142,"domain_scores_codex":[0.9994937,0.0002262434,0.00003841576,0.00008238265,0.00005462178,0.0001047085],"domain_scores_gemma":[0.9992195,0.0002645332,0.0001328615,0.00005573663,0.00005271052,0.0002745796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9716662,0.003869603,0.0005321034,0.0004873156,0.0006329581,0.00006263797,0.00004487656,0.0002545072,0.004237653,0.00009628465,0.000668733,0.01744706],"study_design_scores_gemma":[0.9334723,0.06248002,0.002116399,0.00002370826,0.0004084633,0.00007870938,0.00002336994,0.0003818826,0.0004065416,0.0001255372,0.000464297,0.00001876632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893476,0.00499986,0.0004048,0.0005361798,0.0003376857,0.0008497459,0.0008640552,0.0001184638,0.002541545],"genre_scores_gemma":[0.9919944,0.001989183,0.0005781392,0.0008804005,0.0003593606,0.0007446072,0.001288112,0.00002325005,0.002142554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006000037,"threshold_uncertainty_score":0.02007216,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04150119976932149,"score_gpt":0.3519479655918908,"score_spread":0.3104467658225693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}